Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>Mark J. Levis, Yves Béguin, Anurag K. Singh et al.|Journal of Clinical Oncology|2024Cited by 204
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCatherine C. Smith, Erkut Bahceci, Mark J. Levis et al.|Blood|2019Cited by 25